1 / 57

Schizophrenia & Psychoses A Clinical Introduction

Schizophrenia & Psychoses A Clinical Introduction . Godfrey D. Pearlson, M.D. Neuropsychiatry Research Center Institute of Living Yale University School of Medicine. Schizophrenia - Outline. 1. Phenomenology 2. Epidemiology 3. Etiology ‑ neurodevelopmental & genetic factors

tea
Download Presentation

Schizophrenia & Psychoses A Clinical Introduction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Schizophrenia & PsychosesAClinical Introduction Godfrey D. Pearlson, M.D. Neuropsychiatry Research Center Institute of Living Yale University School of Medicine

  2. Schizophrenia - Outline 1. Phenomenology 2. Epidemiology 3. Etiology ‑ neurodevelopmental & genetic factors 4. Spectrum disorders, biomarkers, • Treatments • Psychotic mood disorders

  3. Core Concepts- 1 Affective Disorder: disturbance of mood Delirium:disturbance ofconsciousness Dementia: disturbance of (a prior level of) cognition Schizophrenia: ?????????????????????? No obvious pathognomonic symptoms or core“theme”.

  4. Core Concepts II 1. Because it has no pathognomonic symptoms, schizophrenia is a diagnosis of exclusion. 2. Widespread agreement that schizophrenia is a heterogeneous disorder; but no agreement on sub-typing. 3. Traditional subtypes (e.g. hebephrenic, paranoid) mutate over time.

  5. DELIRIUMPLUS DISTURBED CONSCIOUSNESS DEMENTIAPLUSCOGNITIVE DECLINE AFFECTIVEPLUS CHANGE IN DISORDER MOOD, SELF-ATTITUDE AND VITAL SENSE SCHIZOPHRENIA HALLUCINATIONS, DELUSIONS, FORMAL THOUGHT DISORDER

  6. SCHIZOPHRENIA– CASE STUDY 1 Frank S. 31 y.o. single WM • Upper middle class family, no FH of mental illness • Mother’s pregnancy – ‘flu’ at 15 weeks, forceps delivery, Apgar in normal range • Shy, slightly withdrawn child – ‘grew out of it’ by age 14. IQ = 128 FS. • College – electrical engineering major. All ‘A’ grades in freshman year. • Sophomore year – age 20, increasingly withdrawn, preoccupied, ‘distant’, odd philosophical worries x 6 months.

  7. SCHIZOPHRENIA– CASE STUDY 2 • Became convinced messages on TV about him, “aliens reading my mind.” “White House controlling my body.” • Auditory hallucinations of “robot voices” saying good and bad things about him, arguing. • Showed up at police HQ to warn of “plots”, taken to ER for evaluation • Alert, O x 3. Not elated or depressed. MMS – 30/30. Urine Toxicology screen negative. Physical exam and labs all WNL. Brain MRI WNL.

  8. SCHIZOPHRENIA– CASE STUDY 3 • Hospitalized three weeks • Partial response to Haloperidol • Family “lost his spark”……but not due to medications • Unable to complete college • Halfway house – small apartment • Volunteer for state agency • 3 subsequent hospitalizations in 10 years • Seclusive, poor self-care • Some improvement on olanzapine – initial gain • Now on ziprasodone – variable compliance

  9. Positive and Negative Symptoms PositiveNegative/Deficit Delusions Poverty of speech Hallucinations Flat affect Incoherence Social Withdrawal Bizarre behavior Apathy (Remember-no pathognomonic symptoms.) Source: DSM-IV Draft Criteria, 1993

  10. Cognitive Deficits An essential part of the syndrome. • Working Memory • Set Shifting • Verbal Memory • Attention / Continuous Performance

  11. Epidemiology of Schizophrenia • About 1% prevalence in the population • Occurs in all cultures, all socioeconomic groups • Peak onset in men, ages 15 to 25 • Peak onset in women, ages 22 to 30 • Prevalence ultimately equal in men and women • 50% of patients attempt suicide, 10% succeed • Most expensive of all mental disorders: Chronic but non-fatal, many incarcerated, homeless • Direct costs = 0.4% of the GNP • Indirect costs = 1.6% of the GNP

  12. 20-year Follow-up of Patients with SZ (Iceland) • All first-episode SZ diagnosed in 1966 to 1967 • 22% mortality and 9% suicide • 60% never married; of the rest, most divorced • 71% had persistent symptoms despite neuroleptic treatment • 95% had impaired social relationships • 65% worked fewer than 5 months per year • 29% had “an acceptable level of health”

  13. Medical Illnesses in Psychosis

  14. Proposed Etiology • Genetic predisposition / vulnerability • Brain mal-development in utero (genetic, toxic, infective) • Pregnancy & birth complications • Early psychosocial experience Source: Mednick et al., 1991

  15. GENE  CELL  SYSTEM  BEHAVIOR

  16. Brain Structure Electro Physiology Sensory motor Integration Cognition Brain Function Clinical Symptoms

  17. Gene Cell System Behavior • Multiple susceptibility alleles, each of small effect, low penetrance, that act in concert • Subtle metabolic abnormalities • Molecular bottlenecks? • Abnormal information processing • Cognitive inefficiency – memory and control processes, Biomarkers • Not ≡ illness, e.g. as found in unaffected siblings • Complex functional interactions • Emergent phenomena (After Weinberger, 2003)

  18. PHASES OF SCHIZOPHRENIA Functioning PREMORBID PRODROME ACTIVE Course of Illness

  19. Environmental StressBiological FactorsDrug Use Disease Genes Viral Infection Environmental Toxins Peri-natal/Birth Complications TRIGGERS: SZ B i o l o g i c a l V u l n e r a b i l i t y Structure Biochem Function Neurol + Cognitive Deficits Early Negative Sx Weak Positive Sx Emerging Psychotic Sx Age 0 12 5 15 18 21 Early Prodrome Late Prodrome Premorbid

  20. Diagnostic Criteria for Schizophrenia • DSM-IV -Based on phenomenology • Highly reliable, but of dubious validity • Could have been written 100 years ago (in fact they were, essentially) • No laboratory test, even to confirm diagnosis, let alone a diagnostic test related to pathophysiology

  21. DIABETESSCHIZOPHRENIA Etiology  • Pathology  • Biologic  • Definition/Test Genes  (partial) • (partial) Biomarkers  (partial)

  22. Clues from Type-2 Diabetes “Spectrum Cases” • Impaired GTT + impaired fasting glucose ~ 40% of obese adults • Gestational DM (~ 10% of pregnant women) • Steroid-induced DM (~ 30% on hi-dose systemic steroids) All of the above are substantially increased in first-degree relatives of Type-2 diabetics (about 50% have insulin resistance), 15% diabetes, 25% abnormal GTT.

  23. Schizotypy and Spectrum Conditions 1 Early researchers into schizophrenia noticed that unaffected family members exhibited oddities and eccentricities. Interpretation: • Consequence of close association with someone whose behavior was disturbed or disturbing • Lesser, “dilute” form of the disorder

  24. Schizotypy and Spectrum Conditions 2 Kety’s genetic studies with the Danish twin and disease registries, & Kendler’s Irish kindreds confirm these ideas. Mild or dilute forms of schizophrenia, or oddities of thought and behavior occur more commonly among close relatives of patients with schizophrenia than in the population at large. Genetic explanations best fit the facts. These individuals have vulnerability genes, insufficient for full-fledged schizophrenia. < Introduces concept of biomarkers >

  25. SCHIZOPHRENIA VULNERABILITY MARKERS “Biomarkers”

  26. BIOMARKERS Definition: Physiological and clinical phenomena found in association with a disorder, which are quantifiable, and presumed to be more closely connected to the vulnerability gene than the illness diagnosis.

  27. Schizophrenia Biomarkers • Gene markers – a few in last 3 yrs. • Electrophysiology – P-300, N-400, P450 • Psychophysiology – oculomotor, PPI • Brain structure – Volumes of LV, STG, Hippo • Brain Function – PET, fMRI with WCST, WM • Brain Chemistry – DA receptors, release • Development – neurologic, cognitive, social • Clinical exam – MPA’s, ‘soft’ neurologic signs • Cognition – WM, attention • Niacin flush, fingerprints

  28. Biomarkers and Schizophrenia • Summary: • Promising avenue of research. • Approach very useful in diabetes, hypertension- may work for schizophrenia.

  29. Schizophrenia and Cognition Major defects in: • Working memory • Executive functioning (abstraction, problem solving, conceptualization, sequencing, inhibition, planning) • Attention • Verbal memory • Semantic tasks Symptoms suggest frontal lobe dysfunction

  30. Cognitive Deficits in Schizophrenia Core Features of Illness Precede Onset of Illness • ½ SD lower IQ • Reading difficulties in grade through high school • Delayed onset of hand dominance Present at Disease Onset Continued… Sources: Green 1996; Heinrichs and Zakzanis 1998; Saykin 1991, 1994

  31. Cognitive Deficits in Schizophrenia Resist Medication Effects Persist into Senescence May Predict Psychosocial Function Better Than Positive or Negative Symptoms

  32. Core Cognitive Domains Compromised in Schizophrenia • Sustained attention • Working memory • Set shifting • Verbal Memory • Problem solving • Abstraction These suggest compromised neural circuits

  33. Symptoms suggestive of frontal lobe dysfunction • Emotional dullness • Impaired judgment • Poor initiative, motivation, drive • Lack of insight • Difficulty in planning • Impaired problem-solving/abstract reasoning • Decreased concern for personal hygiene • Social withdrawal

  34. Cognitive Rehabilitation • Remediation- Repeated practice and acquisition of compensatory strategies on cognitive exercises designed to engage under-functioning brain circuits Adaptation

  35. History of Antipsychotic Medications

  36. Dopamine and other Neurotransmitters

  37. Atypical neuroleptics • Off D2 graph • Other receptors • Antipsychotic with EPS! • Effective against negative symptoms (late!) • Atypically expensive

  38. Annual Cost Estimates of Typical Doses Clozaril (Sandoz) $3,694 (Not including monitoring , which adds significant extra cost) 5 mg. BID, Haldol $944 (McNeil) Haldol (Generic) $254 3 mg. BID, Risperdal $2,843 (Janssen) 10mg of Zyprexa $1/mg = $3,650 (Pfizer)

  39. Psychosis in Mood Disorders

  40. Phenomenology and Schneider’s First-Rank Symptoms • Kurt Schneider, 1939, places high value on certain symptoms in the diagnosis of schizophrenia, naming them “ first rank symptoms”. • These include: audible thoughts, voices heard arguing, voices heard commenting on one's actions, somatic passivity experiences, thought withdrawal & diffusion, delusional perception, and “made” impulses, drives and volitional acts experienced by the patient as the work or influence of others. • “When any of these modes of experience is undeniably present and no basis of somatic illness can be found, we may make the decisive clinical diagnosis of schizophrenia.”

  41. Why we Downgraded FRS • Three sets of observations tend to undermine this distinction. These come from the work of Gabrielle Carlson, Carpenter and Strauss and the St. Louis group. • First-rank symptoms occur commonly in cases of mania (up to 40%). • Not useful in terms of diagnostic distinction, do not predict outcome of illness or response to treatment.

  42. Carlson describes a “third stage" of mania • Manifested by bizarre behavior, mood-incongruent hallucinations & delusions paranoia and extreme dysphoria. • “Despite symptoms that might have otherwise prompted the diagnosis of schizophrenia, …. patients appeared clearly manic both earlier in the course and later as the episode was resolving.”

  43. Example from Carlson: • Patient frightened, talking and crying constantly, pacing. “I will never get out”. “I have cats eyes”. “He crawls around inside me, and he cannot stand the light.” Profane, hypersexual, uncooperative. “Oh please let me die, I can’t take it anymore”. “National Institute of Hell.” • Following treatment, patient reverted to a typical manic state: hypersexual, bizarre attire (wearing three dresses at a time), grandiose, incessant talking.

More Related